Arthritis Treatment Drug Guide,Arthritis Treatment,Arthritis Drug,Rheumatoid arthritis,Dmard,Nsaids,Synova Total Joint Care with Glucosamine, Chondroitin, MSM for Osteo and Rheumatoid Arthritis - 60 Coated Caplets

Rheumatoid arthritis drugs.: An article from: Internal Medicine News

Prod­uct Descrip­tion­This dig­i­tal doc­u­ment is an arti­cle from Inter­nal Med­i­cine News, pub­lished by Thom­son Gale on Sep­tem­ber 15, 2005. The length of the arti­cle is 756 words. The page length shown above is based on a typ­i­cal 300-word page. The arti­cle is deliv­ered in HTML for­mat and is avail­able in your Ama­zon. com Dig­i­tal Locker imme­di­ately after pur­chase. You can view it with any web browser. Cita­tion Detail­sTi­tle: Rheuma­toid arthri­tis drugs. (DRUGS, PREGNANCY, AND LACTATION)Author: Ger­ald G. Brig­gsPub­li­ca­tion: Inter­nal Med­i­cine News (Magazine/Journal)Date: Sep­tem­ber 15, 2005Publisher: Thom­son GaleVol­ume: 38 Issue: 18 Page: 30(1)Distributed by Thom­son Gale

Rheuma­toid arthri­tis drugs.: An arti­cle from: Inter­nal Med­i­cine News

Immune-system injuries prompt suits over arthritis drugs.: An article from: Trial

Prod­uct Descrip­tion­This dig­i­tal doc­u­ment is an arti­cle from Trial, pub­lished by Asso­ci­a­tion of Trial Lawyers of Amer­ica on April 1, 2004. The length of the arti­cle is 1571 words. The page length shown above is based on a typ­i­cal 300-word page. The arti­cle is deliv­ered in HTML for­mat and is avail­able in your Ama­zon. com Dig­i­tal Locker imme­di­ately after pur­chase. You can view it with any web browser. Cita­tion Detail­sTi­tle: Immune-system injuries prompt suits over arthri­tis drugs. Author: Sara Hoff­man Jurand­Pub­li­ca­tion: Trial (Magazine/Journal)Date: April 1, 2004Publisher: Asso­ci­a­tion of Trial Lawyers of Amer­i­caVol­ume: 40 Issue: 4 Page: 12(3)Distributed by Thom­son Gale

Immune-system injuries prompt suits over arthri­tis drugs.: An arti­cle from: Trial

Freedom from Rheumatoid Arthritis: The amazing story of one woman’s recovery

Prod­uct Descrip­tion­Free­dom from Rheuma­toid Arthri­tis is an inspi­ra­tional book about sur­vival. It tells the story of how one woman went from being a bed rid­den crip­ple on and off for a year and a half, to reclaim­ing her health, hap­pi­ness and qual­ity of life stolen from her by this insid­i­ous dis­ease. It is the story of a jour­ney, a jour­ney of dis­cov­ery under­taken by one fiercely deter­mined woman. A woman who has been to the depths and healed her­self, and now with con­sum­mate com­pas­sion and grace, offers to share that process with you. This book includes a seven day menu, recov­ery and main­te­nance diet and recipes. 

Free­dom from Rheuma­toid Arthri­tis: The amaz­ing story of one woman’s recovery

Celecoxib for JRA under surveillance.: An article from: Family Practice News

Prod­uct Descrip­tion­This dig­i­tal doc­u­ment is an arti­cle from Fam­ily Prac­tice News, pub­lished by Thom­son Gale on Jan­u­ary 15, 2007. The length of the arti­cle is 545 words. The page length shown above is based on a typ­i­cal 300-word page. The arti­cle is deliv­ered in HTML for­mat and is avail­able in your Ama­zon. com Dig­i­tal Locker imme­di­ately after pur­chase. You can view it with any web browser. Cita­tion Detail­sTi­tle: Cele­coxib for JRA under sur­veil­lance. (News)(drug approvals for juve­nile rheuma­toid arthritis)Author: Eliz­a­beth Mech­catiePub­li­ca­tion: Fam­ily Prac­tice News (Magazine/Journal)Date: Jan­u­ary 15, 2007Publisher: Thom­son GaleVol­ume: 37 Issue: 2 Page: 7(1)Distributed by Thom­son Gale

Cele­coxib for JRA under sur­veil­lance.: An arti­cle from: Fam­ily Prac­tice News

The best For DMARD-resistant rheumatoid arthritis patient.

The best For DMARD-resistant rheuma­toid arthri­tis patient.

From  Rit­ux­imab use in every­day clin­i­cal prac­tice as a first-line bio­logic ther­apy for the treat­ment of DMARD-resistant rheuma­toid arthritis

D. McGonagle1,2, A. L. Tan2, J. Madden1, L. Taylor1 and P. Emery2

1Department of Rheuma­tol­ogy, Calderdale Royal Hos­pi­tal, Salter­heb­ble, Hal­i­fax and 2Academic Unit of Mus­cu­loskele­tal Dis­ease, Uni­ver­sity of Leeds and Chapel Aller­ton Hos­pi­tal, Leeds, UK.

RA is the com­mon­est inflam­ma­tory arthropa­thy and affects nearly half a mil­lion patients in the UK. The cur­rent first-line treat­ment uti­lizes DMARDs that often have sub­op­ti­mal responses . The intro­duc­tion of TNF inhibitors offered a new option for patients with DMARD-resistant dis­ease . Upon the licens­ing of anti-TNF agents, the health care ser­vice struc­ture of the UK meant that lit­er­ally hun­dreds of thou­sands of patients were poten­tially suit­able for ther­apy. Given the costs of ther­apy, the pre­scrib­ing of anti-TNF agents for inflam­ma­tory arthri­tis has been patchy, which has restricted the avail­abil­ity of anti-TNF agents in some regions .Rit­ux­imab in com­bi­na­tion with MTX was licensed in the UK in 2006 for the treat­ment of adult patients with severe active RA who have had an inad­e­quate response to, or been intol­er­ant to con­ven­tional DMARDs and one or more TNF inhibitors. How­ever, the early clin­i­cal stud­ies that demon­strated the effi­cacy of rit­ux­imab in RA were car­ried out in patients who had not pre­vi­ously received TNF inhibitors . Rec­og­niz­ing that rit­ux­imab was going to be licensed for RA and due to the inabil­ity to obtain anti-TNF ther­apy, we have used rit­ux­imab as a first-line bio­log­i­cal agent between 2004 and early 2007. In this arti­cle, we report our expe­ri­ence for the treat­ment of RA in daily clin­i­cal prac­tice in a non-academic centre.

This study reports the use of rit­ux­imab for RA in a ‘real world’ non-academic envi­ron­ment in patients, the vast major­ity of whom had not pre­vi­ously received anti-TNF ther­apy. A recent report showed the effi­cacy of rit­ux­imab in RA in a sim­i­lar sit­u­a­tion , but the patients in ques­tion had failed anti-TNF ther­apy, whilst our report focused mainly on patients who failed DMARDs only. Almost half the cases had dis­ease where some rheuma­tol­o­gists would have con­cerns about using anti-TNF agents includ­ing risks of infec­tion and strong ANA pos­i­tiv­ity. We found that rit­ux­imab was extremely well tol­er­ated. Based on the expe­ri­ence in haema­tol­ogy and oncol­ogy it would appear that the short-term safety data of rit­ux­imab is at least as good as the anti-TNF agents [14]. For exam­ple, there is no appar­ent increased risk of seri­ous infec­tions includ­ing tuber­cu­lo­sis. Con­cerns have also been raised that the anti-TNF agents may be asso­ci­ated with an increased long-term risk of lym­phoretic­u­lar malig­nan­cies includ­ing lym­phomas, some of which rit­ux­imab is licensed to treat . In the case of malig­nancy, rit­ux­imab has been pre­dom­i­nantly used as a sin­gle course of therapy.

Con­clu­sions. Rit­ux­imab is well tol­er­ated in every­day clin­i­cal prac­tice and may rep­re­sent a good short-term treat­ment option where anti-TNF ther­apy is either unavail­able or rel­a­tively contraindicated.

New Arthritis Drugs Fast, Effective.: An article from: Family Practice News

Prod­uct Descrip­tion­This dig­i­tal doc­u­ment is an arti­cle from Fam­ily Prac­tice News, pub­lished by Inter­na­tional Med­ical News Group on Octo­ber 1, 2000. The length of the arti­cle is 801 words. The page length shown above is based on a typ­i­cal 300-word page. The arti­cle is deliv­ered in HTML for­mat and is avail­able in your Ama­zon. com Dig­i­tal Locker imme­di­ately after pur­chase. You can view it with any web browser. Cita­tion Detail­sTi­tle: New Arthri­tis Drugs Fast, Effec­tive. (etan­er­cept and infliximab)Author: Nancy Wal­sh­Pub­li­ca­tion: Fam­ily Prac­tice News (Magazine/Journal)Date: Octo­ber 1, 2000Publisher: Inter­na­tional Med­ical News GroupVol­ume: 30 Issue: 19 Page: 14Distributed by Thom­son Gale

New Arthri­tis Drugs Fast, Effec­tive.: An arti­cle from: Fam­ily Prac­tice News

MAGNETIC THERAPY Right Hand Support for CARPAL TUNNEL & ARTHRITIS PAINS

  • Pow­er­ful Med­ical Mag­nets heal mus­cle spasms and irri­tated lig­a­ments due to Carpal Tun­nel Syn­drome, Chronic Hand and Wrist Pain.
  • Med­ically test proven to be the most effec­tive mag­net for Pain Relief. Med­ical Stud­ies Online
  • Heals pain and swelling due to arthri­tis, repet­i­tive motion chronic hand and wrist pain.
  • Eases swelling and improves cir­cu­la­tion for speedy healing
  • Com­fort­ably sup­ports wrist and hand pre­vent­ing awk­ward sleep­ing positions

Prod­uct Descrip­tio­nOur Mag­netic Ther­apy, for day­time and night­time PAIN RELIEF has been Med­ically test proven, at major Med­ical Cen­ters, to effec­tively increase blood cir­cu­la­tion and pro­vide out­stand­ing pain relief These ther­a­peu­tic mag­nets reduce swelling and pain, expe­dit­ing the heal­ing process for chronic and acute con­di­tions.
Our mag­netic ther­apy pro­vides excel­lent results whether the con­di­tions are acute or chronic. 

SEE A FULL SELECTION OF WRIST PAIN RELIEF PRODUCTS AT
WWW. MAGNETICPRODUCTS. COM

MAGNETIC THERAPY Right Hand Sup­port for CARPAL TUNNEL & ARTHRITIS PAINS

DMARDs in Treatment of Rheumatoid Arthritis

DMARDs in Treat­ment of Rheuma­toid Arthritis

Ther­apy of rheuma­toid arthri­tis (RA) focuses on the retar­da­tion and, ide­ally, halt­ing of the nat­ural course of the dis­ease using disease-modifying anti-rheumatic drugs (DMARDs) . How­ever, insuf­fi­cient effi­cacy of DMARDs and a sig­nif­i­cant degree of tox­i­c­ity lead to rel­a­tively low reten­tion rates for these drugs . As a con­se­quence, RA patients are likely to receive sev­eral com­pounds con­sec­u­tively dur­ing the course of their chronic dis­ease. We also describe the pat­tern of ini­tial DMARDs employed in new patients over the past two decades. We also explored the pre­ferred DMARDs when pre­ced­ing ones had failed. Finally, our data may pro­vide a basis for expec­ta­tions and future mea­sures of suc­cess of tra­di­tional as well as the new, recently approved DMARDs.

RheumatoidArthritis

The influ­ence of selec­tion bias on the iden­ti­fied patients is con­sid­ered very low, as data were extracted from the files in 1999 but files of all RA patients, includ­ing those with long-standing RA, who were seen in the out-patient clin­ics at least once after 1993, are kept in the archives. There­fore, charts of patients who were lost to follow-up or had died since 1993 were also avail­able, and the only charts that were not avail­able for analy­sis were those for patients who had no visit after 1993. To deter­mine the poten­tial pres­ence and degree of bias, we analysed dis­ease dura­tion for ther­a­pies and rea­sons for treat­ment dis­con­tin­u­a­tion before and after 1993, and found no sig­nif­i­cant difference.

Five hun­dred and ninety-three patients were iden­ti­fied in the two clin­ics and were fol­lowed through­out their DMARD ther­a­pies until the last eval­u­a­tion in 1999. The ratio of women to men was 4:1. Test­ing for rheuma­toid fac­tor at the time of first pre­sen­ta­tion at the clin­ics was pos­i­tive in 379 patients (63.9%) and neg­a­tive in 214 (36.1%). The patients’ mean age (±S.D.) at the time of study was 59.1±13.6 yr and the mean dis­ease dura­tion was 12.1±9.3 yr. These patients received a total of 1319 courses of DMARDs. The num­ber of DMARD courses pre­scribed to an indi­vid­ual RA patient ranged from 1 to 10 (median 2). A total of 2376 patient-years (p.y.) of DMARD ther­apy were analysed and involved the fol­low­ing ther­a­pies (num­bers of p.y. are rounded): aura­nofin (OG; n=68, 131 p.y.), aza­thio­prine (AZP; n=25, 56 p.y.), anti­malar­i­als (AM; n=285, 536 p.y.), cyclosporin A (CyA; n=31, 27 p.y.), D-penicillamine (DPA; n=65, 164 p.y.), methotrex­ate (MTX; n=389, 751 p.y.), par­enteral gold com­pounds (PG; n=109, 218 p.y.), sul­phasalazine (SSZ; n=267, 428 p.y.) and com­bi­na­tion ther­a­pies (Comb.; n=80, 67 p.y.).

The data reveal that CQ, SSZ and MTX were used to a sim­i­lar extent in the early phase of ther­apy. Cer­tain char­ac­ter­is­tics of the patients or their dis­ease must have led to the choice of either one of these drugs, as the efficacy/toxicity trade-offs are sim­i­lar for these drugs. In fact, the acute-phase response at treat­ment ini­ti­a­tion was sig­nif­i­cantly higher in patients on MTX than in those who were begin­ning CQ  or SSZ.        MTX was the most com­monly employed DMARD ther­apy for RA and was used increas­ingly as first ther­apy in newly diag­nosed RA. Patients with high dis­ease activ­ity were given MTX ther­apy more often than other DMARDs, while those with low activ­ity were more likely to receive SSZ or AM, and MTX on fail­ure of these drugs. First DMARDs in new patients were retained longer than sub­se­quent DMARDs, appar­ently because they are more effective.

Arthritis drug holds promise in severe vasculitis.: An article from: Skin & Allergy News

Prod­uct Descrip­tion­This dig­i­tal doc­u­ment is an arti­cle from Skin & Allergy News, pub­lished by Thom­son Gale on Feb­ru­ary 1, 2007. The length of the arti­cle is 926 words. The page length shown above is based on a typ­i­cal 300-word page. The arti­cle is deliv­ered in HTML for­mat and is avail­able in your Ama­zon. com Dig­i­tal Locker imme­di­ately after pur­chase. You can view it with any web browser. Cita­tion Detail­sTi­tle: Arthri­tis drug holds promise in severe vas­culi­tis. (Clin­i­cal Rounds)Author: Nancy Wal­sh­Pub­li­ca­tion: Skin & Allergy News (Magazine/Journal)Date: Feb­ru­ary 1, 2007Publisher: Thom­son GaleVol­ume: 38 Issue: 2 Page: 69(1)Distributed by Thom­son Gale

Arthri­tis drug holds promise in severe vas­culi­tis.: An arti­cle from: Skin & Allergy News

The Arthritis Handbook: Improve Your Health and Manage the Pain of Osteoarthritis

  • ISBN13: 9780979356414
  • Con­di­tion: NEW
  • Notes: Brand New from Pub­lisher. No Remain­der Mark.

Prod­uct Descrip­tionAc­cord­ing to con­ven­tional wis­dom, arthri­tis pain is an inevitable part of aging. Not so, says Dr. Grant Cooper in this prac­ti­cal, acces­si­ble guide. For those who do develop osteoarthritic con­di­tions, this book offers a blend of com­mon­sense advice, dietary info, tar­geted exer­cise, and tips on use­ful sup­ple­ments. Accord­ing to the author, suf­fer­ers can often entirely avoid the use of med­ica­tion, injec­tion ther­apy, and surgery — approaches that, when nec­es­sary, can be used as an oppor­tu­nity to return to exer­cise and nutri­tion to slow the disease’s progress. The book fea­tures easy, illus­trated exer­cises, includ­ing aer­o­bics and strength train­ing, that can be done at home, at a gym, or under a trainer’s or phys­i­cal therapist’s super­vi­sion. Nutri­tional and sup­ple­ment strate­gies — includ­ing glu­cosamine and fish oil — are pre­sented in detail, along with sug­ges­tions for ways to keep on track. Dr. Cooper not only explores each topic in depth but explains how it fits into an over­all holis­tic treat­ment program. 

The Arthri­tis Hand­book: Improve Your Health and Man­age the Pain of Osteoarthritis